Health Care • Industrial Specialties
$432.01 ▼ -16.75
(-3.73%)
MKT CAP: $155.56B • VOL: 3.48M
52W L $329 52W H $604
ISRG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $10.06B | $8.35B | $7.12B |
| YoY Revenue Growth % | +20.5% | +17.2% | — |
| Gross Profit | $6.64B | $5.63B | — |
| Gross Margin % | 66.0% | 67.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.95B | $2.35B | $1.77B |
| Operating Margin % | 29.3% | 28.1% | 24.8% |
| Net Income (GAAP) | $2.86B | $2.32B | $1.80B |
| EBITDA (Normalized) | $3.31B | $2.65B | $2.02B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.03B | $2.42B | $1.81B |
| Capital Expenditures (CapEx) | $452.9M | $375.8M | $320.6M |
| Free Cash Flow (FCF) | $2.58B | $2.04B | $1.49B |
| FCF Margin % | 25.6% | 24.4% | 21.0% |
| Return on Invested Capital (ROIC %) | 14.9% | 12.0% | 2.7% |
| Cash & Short-Term Equivalents | $3.37B | $2.03B | — |
| Total Debt (Short + Long Term) | $1.13B | $996.1M | $20.02B |
| Total Stockholders' Equity | $17.82B | $16.43B | $41.07B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ISRG.